
# Viral Hepatitis





### Prof. MUDr. Petr Husa, CSc. Klinika infekčních chorob, FN Brno


## Viral Hepatitis

- 1. <u>Enterically transmitted</u>
- VH A only acute
- VH E rare chronic (immunosuppressed pts.)
- 2. <u>Parenterally transmitted possible chronic stage</u>
- VH B
- VH C
- VH D


# **Healthy liver**










# Liver fibrosis












# Liver cirrhosis


























# Hepatocellular carcinoma








## Viral Hepatitis in CR 2006-2015

	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
VHA	132	128	1648	1104	862	264	284	348	673	723
VH B	307	307	306	247	244	192	154	133	105	90
VH C	1022	980	974	836	709	812	794	873	867	945
VH E	35	43	65	99	72	163	258	218	299	409


### Hepatitis A virus (HAV)




family Picornaviridae, genus Hepatovirus - non-enveloped RNA, 27 nm

# **Hepatitis** A

-Ann




n




# Epidemiology

- Fecal –oral route of transmission
- ✓ Contaminated hands or daily used instruments
- ✓ Contaminated drinking water
- ✓ Contaminated food
- Vaccination available, recommended especially fore travelers to countries with lower standard of hygiene


#### Concentration of Hepatitis A Virus in Various Body Fluids





#### Hepatitis B Virus (HBV)

#### **Hepatitis B Virus**




family Hepadnaviridae, enveloped DNA virus, 42 nm

#### Global significance of HEP B


- One of the biggest global health problems
- ✓ More than 2 billions of infections during the life
- ✓ 350-400 million chronic carriers China (125 million), Brazil (3,7 million), South Korea (2,6 million), Japan (1,7 million), USA (more than 1 million), Italy (900 thousand).
- ✓ 25-40 % chronic carriers have LC or HCC, 0,5-1,0 million deaths due to decompensated LC or HCC
- $\checkmark$  50 thousand death annually due to fulminant hepatitis
- ✓ Global vaccination in 177 countries (2008)



# Hepatitis **B**



# Countries using HepB in national immunization schedule, 2008



Source: WHO/IVB database, 193 WHO Member States. Data as of August 2009 Date of slide: 24 November 2009

The boundaries and a constraint and the designment wind as the samp do an empiry the expression of any represervations are the part of the World Heads Coperations concerning the legisl success of any resurvey, security are protoned on the succession of the deformation of the formation as boundaries. Detect have an anyotrapic conception to have fair which have carry as you be full approximate. DWHO 2000 All inplaces conceptions




No HepB (16 countries' or 8%) HepB no Birth Dose (92 countries<sup>2</sup> or 48%) HepB with Birth Dose (85 countries<sup>3</sup> or 44%)

ักเรโบชีอ เกิดสะสมกับอาหาที่ อส์สไอสสาร์ เการมกละเอก วิทธาับชีอ 2.เสียาหาที่ jamia เกทียส์แสาลก วิทธาับชื่อ ลิเซีอ หาที่ jamia' เกทียส์แสาลก



# Number of countries having introduced HepB vaccine\* and global infant coverage, 1989-2008



- \* Year of introduction can be the year of partial introduction
- \*\* Includes India and Sudan with partial introduction excluding 3 countries where HepB administered for adolescence

Source: WHO/UNICEF coverage estimates 1980-2008, August 2009, 193 WHO Member States. Date of slide August 2009



#### Hepatitis B in Czech Republic

- Still important infection but incidence and prevalence are gradually decreasing
- ✓ Prevalence of chronic carriers was  $0.56 \% (2001) \dots 0,064 \% (2013)$
- ✓ Decrease of prevalence and incidence due to vaccination of high-risk persons (health care workers, newborns of HBsAg-positive mothers, before hemodialysis)
- ✓ Global vaccination of all newborns and 12-years old children 2001-2013, now only newborns (haxavaccine)

# Epidemiology of HBV

#### Transmission

- $\checkmark$  blood and blood products
- ✓ sexual intercourse
- $\checkmark$  organ and tissue transplant recipients
- $\checkmark$  vertically from mother to newborn
- Who is in the highest risk in well-developed countries?
- ✓ intravenous drug abusers
- ✓ persons with multiple sexual partners






#### Clinical pictures of acute HEP B

- IP: 30–180 days (mostly 2–3 months)
- Prodromal stage flu-like syndrome
- Fulminant hepatitis: < 1 %
- Chronic HBV infection mortality: 15 25 %




Propojený obrázek netre zobrazit. Příslušný soubor byl pravděpodotně přesurut, přejmenován nebo odstraněn. Ověřte, zda propojení odkazuje na správný soubor a umísti



Propojený obrázek netre zobrazit. Příslušný soubor byl pravděpodotně přesurut, přejmenován nebo odstraněn. Ověřte, zda propojení odkazuje na správný soubor a umísti


Propojený obrázek netre zobrazit. Příslušný soubor byl pravděpodotně přesurut, přejmenován nebo odstraněn. Ověřte, zda propojení odkazuje na správný soubor a umísti

# Hepatitis C virus (HCV)



family Flaviviridae, genus Hepacivirus, enveloped RNA virus 60 nm

# Hepatitis C



World Health Organization. Wkly Epid Rec .1999;74:425-427. World Health Organization. Hepatitis C: Global Prevalence: Update. 2003. Farci P, et al. Semin Liver Dis. 2000;20:103-126. Wasley A, et al. Semin Liver Dis. 2000;20:1-16.

# Distribution of HCV genotypes





# Hepatitis C


- Significant global health problem
- ✓ about 3 % of the world population are chronically infected with HCV
- ✓ In well-developed countries about 20 % of all acute hepatitis, 70 % chronic hepatitis, 40 % cirrhosis, 60 % HCC and indication to 30 % liver transplantations
- In Czech Republic
- ✓ prevalence 0,2 % (2001)
- No vaccine, no hyper-immune immunoglobulin

## Epidemiology of HEP C

- Transmission:
- ✓ blood and blood products
- $\checkmark$  sharing of used injection needles and syringes
- ✓ sexually (rare)
- ✓ vertically (rare)
- Who is in the highest risk of HCV infection at present?
- ✓ intravenous drug abusers
- Infection is frequently diagnosed in chronic stage

### Patients with higher risk of HCV infection

- ✓ Intravenous drug abusers (sharing of injection needles and syringes)
- Recipients of blood transfusions before the year 1992 (especially hemophiliacs)
- $\checkmark$  Persons with tattoo or piercing




# Clinical course of HEP C

- Acute hepatitis is mostly asymptomatic
- Probability of chronicity is high (40-50% till 90-100%).
- Higher probability of chronicity:
- $\Rightarrow$  Older persons
- ⇒ Higher initial infection dose (transfusion versus needles)
- ⇒ HBV, HIV co-infection
- ⇒ abusus of alcohol
- ⇒ immunodeficiency


# Clinical course of HEP C

- LC in about 20 % patients with chronic HCV infection
- HCC annually in 1-4 % patients with LC
- Progression to HCC depends on:
- ✓ age (more rapid progression in older persons)
- $\checkmark$  alcohol abuse
- ✓ HIV co-infection
- ✓ HBV co-infection




# Diagnosis of HCV infection

Anti-HCV are total antibodies against HCV – not division into IgM and IgG class !



### Hepatitis D Virus (HDV)

#### **Hepatitis D (Delta) Virus**




Satelite virus, family Deltaviridae, enveloped RNA, 40 nm

### Hepatitis D

- Ability of replication only in presence of HBV infection
- ✓ Co-infection (better prognosis)
- ✓ Super-infection (worse prognosis)
- Endemic in South America, Mediterranean Region, Romania, Central Africa
- Very low prevalence in CR

# Anti-HDV prevalence in HBsAg-positive (approximately 5%)



# Epidemiology of HDV in Europe

1980s

Endemic
In risk groups

Drug addicts

Rizzetto M. EASL 2009

# **Epidemiology of HDV in Europe**

2009

# Endemic In risk groups


immigrants

Rizzetto M. EASL 2009

-


2010






Family Hepeviridae, genus Hepevirus, non-enveloped RNA virus, 27-34 nm

# HEV genotypes




Purcell RH, Emerson SU. J Hepatol 48 (2008) 494-503

### Hepatitis E in Southern Moravia




#### Hepatitis E

- Travel-related disease (G-1+2 faecely contaminated water)
- Infection is currently more frequently acquired in CR (G-3 pork, game meat)
- Extremely serious clinical course in late pregnancy (mortality above 20 %) and in patients with alcoholic liver cirrhosis (mortality 60-70%)
- Repeated infection may be possible
- Rare cases of chronic hepatitis E in seriously immunosuppressed patients (organ recipients...)




# Figatellu – sausage with raw pork liver





### Rapid progression of chronic hepatitis E



Donor

Recipient

Fig. 1. Histologic assessment of the liver tissue before and after OLT and CT scan after OLT. (A) The liver tissue of the donor revealed absence of significant signs of chronic hepatitis but vesicular fatty liver disease was diagnosed. (B) Second biopsy. One hundred and fifty days after OLT, chronic inflammation with portal and interface hepatitis was described which was interpreted as an acute rejection. (C) Third biopsy. Three hundred and forty seven days after OLT, persistence of chronic hepatitis was associated with portal and septal bridging signs of fibrosis. (D) CT scan performed 1 year after liver transplantation revealed signs of portal hypertension including ascites, splenomegaly and gastric varices compatible with decompensated liver cirrhosis.

### Treatment of acute hepatitis (all types)

- Symptomatic for all types
- $\checkmark$  physical and mental rest
- ✓ diet
- $\checkmark$  no alcohol, no hepatoxic drugs
- ✓ supportive treatment (silymarin, essential phosholipids)



# Current possibilities of treatment of HBV infection

- pegylated interferon alfa-2a 48 weeks
- entecavir for naive patients
- **tenofovir** both for naive and lamivudine-resistant patients

### Drugs for hepatitis C therapy

- ✓ PEG-IFN alfa-2a, -2b
- ✓ Ribavirin
- ✓ Boceprevir (BOC) protease inhibitor of the 1st generation
- ✓ Telaprevir (TVR) protease inhibitor of the 1st generation
- Sofosbuvir (SOF) since January 2014 nucleotide inhibitor of NS5B polymerase
- Simeprevir (SMV) since May 2014 new wave of protease inhibitor of the 1st generation
- ✓ Daclatasvir (DCV) since August 2014 NS5A inhibitor
- Ledipasvir (LDV) since November 2014 NS5A inhibitor only fixed combination with SOF
- ✓ 3D kombinace since January 2015 paritaprevir/ritonavir PI, ombitasvir NS5A, dasabuvir non-nucleoside polymerase inhibitor

## IFN-free regimens for HCV infection

- Very probably the future of HCV therapy
- Combination of oral drugs
- High efficacy
- Almost no adverse events
- Short duration of therapy 12-24 weeks

## Hepatitis D therapy

- very problematic low efficacy
- PEG-IFN long-term (more than 1 year)
- TDV, TDV not effective

### Chronic hepatitis E therapy

- Still unknown
- Only case reports with ribavirin in various therapeutic regimens

# Thank you for your attention!

